AMT vs CCI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMT exhibits significant fundamental instability, evidenced by a mediocre Piotroski F-Score of 4/9 and a critical disconnect between its current price ($175.30) and its Graham Number ($30.85). The company is facing a severe earnings contraction (-33.2% YoY) and maintains an unsustainable dividend payout ratio of 125.93%. High leverage (Debt/Equity 4.34) combined with poor short-term liquidity (Current Ratio 0.40) suggests elevated financial risk. Despite bullish analyst targets, the deterministic data indicates a heavily overvalued asset with deteriorating health.
Crown Castle Inc. (CCI) trades at a premium valuation despite deteriorating fundamentals, including negative earnings growth, declining revenue, and deeply negative profitability metrics. While the stock offers a high dividend yield of 4.64%, the 222% payout ratio and negative ROE of -206.68% raise serious sustainability concerns. Price performance has underperformed over the past 5 years (-30.4%) with continued downward momentum in the last year (-5.9%), contrasting with mixed analyst sentiment that maintains a $116 target. Insider selling worth $4.78M in the past six months and erratic earnings surprises—particularly the catastrophic -2721% miss in Q1 2025—signal internal caution and execution risk.
Compare Another Pair
Related Comparisons
AMT vs CCI: Head-to-Head Comparison
This page compares American Tower Corporation (AMT) and Crown Castle Inc. (CCI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.